Bio-Rad Laboratories (BIO) News Today $361.79 +2.93 (+0.82%) As of 01/31/2025 03:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sivik Global Healthcare LLC Makes New $3.29 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Sivik Global Healthcare LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the medical research company's stock, valued at apJanuary 30 at 9:34 AM | marketbeat.comSG Americas Securities LLC Purchases 1,966 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)SG Americas Securities LLC lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 156.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,221 shares of the medical research company's stJanuary 29 at 3:14 AM | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company.January 28, 2025 | marketbeat.comFifth Third Bancorp Sells 2,993 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Fifth Third Bancorp decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,425 shares of the medical researJanuary 28, 2025 | marketbeat.comBio-Rad Laboratories Inc (BIO) Announces Upcoming Financial Results ReleaseJanuary 27, 2025 | gurufocus.comBio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025January 27, 2025 | businesswire.comBio-Rad Laboratories, Inc. (NYSE:BIO) Short Interest Up 18.8% in DecemberBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 655,500 shares, an increase of 18.8% from the December 15th total of 551,600 shares. Based on an average daily trading volume, of 183,600 shares, the short-interest ratio is currently 3.6 days. Currently, 3.4% of the company's stock are short sold.January 19, 2025 | marketbeat.com87,487 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Wedge Capital Management L L P NCWedge Capital Management L L P NC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 87,487 shares of the medical research company's stoJanuary 18, 2025 | marketbeat.com1,731 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Contravisory Investment Management Inc.Contravisory Investment Management Inc. bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,731 shares of the medical research companyJanuary 16, 2025 | marketbeat.comZacks Research Has Positive Forecast for BIO FY2024 EarningsBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research raised their FY2024 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report issued on Wednesday, January 15th. Zacks Research analyst R. Department now expects that the medical reJanuary 16, 2025 | marketbeat.comBio-Rad Laboratories' (BIO) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday.January 14, 2025 | marketbeat.comDiversified Trust Co Acquires Shares of 2,916 Bio-Rad Laboratories, Inc. (NYSE:BIO)Diversified Trust Co acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,916 shares of the medical researchJanuary 10, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 4,840 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)JPMorgan Chase & Co. decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 8.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,136 shares of theJanuary 10, 2025 | marketbeat.comBio-Rad Laboratories Leads $105 Million Series C Funding for GeneoscopyJanuary 8, 2025 | gurufocus.comBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have received an average recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have issued a buy raJanuary 3, 2025 | marketbeat.comBio-Rad Laboratories Inc (BIO) to Engage with Analysts and Investors at J.P. ...January 2, 2025 | gurufocus.comBio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare ConferenceJanuary 2, 2025 | businesswire.comShort Interest in Bio-Rad Laboratories, Inc. (NYSE:BIO) Rises By 12.9%Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 551,600 shares, an increase of 12.9% from the November 30th total of 488,600 shares. Based on an average daily volume of 196,500 shares, the days-to-cover ratio is currently 2.8 days. Approximately 2.9% of the shares of the company are short sold.December 30, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 21,669 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 95.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,341 shares of the medical research company's stock after purcDecember 29, 2024 | marketbeat.comTidal Investments LLC Sells 2,077 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Tidal Investments LLC trimmed its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 70.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 883 shares of the medical research company's stock after selling 2,077 shares durinDecember 25, 2024 | marketbeat.comQ4 EPS Forecast for Bio-Rad Laboratories Cut by AnalystBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Analysts at Zacks Research dropped their Q4 2025 EPS estimates for Bio-Rad Laboratories in a research report issued on Wednesday, December 18th. Zacks Research analyst R. Department now expects that the medical research company will post earniDecember 23, 2024 | marketbeat.comFY2024 Earnings Estimate for BIO Issued By Zacks ResearchBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research increased their FY2024 earnings estimates for Bio-Rad Laboratories in a research note issued on Wednesday, December 18th. Zacks Research analyst R. Department now forecasts that the medical research company wilDecember 20, 2024 | marketbeat.comGeode Capital Management LLC Reduces Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Geode Capital Management LLC lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 32.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 323,908 shares of the medical reseDecember 19, 2024 | marketbeat.comRetirement Systems of Alabama Acquires 18,760 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Retirement Systems of Alabama boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 416.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,260 shares of the medicDecember 18, 2024 | marketbeat.comFranklin Resources Inc. Reduces Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Franklin Resources Inc. reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 117,243 shares of the medical research company's stock after selling 3,469 sDecember 18, 2024 | marketbeat.comWellington Management Group LLP Grows Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Wellington Management Group LLP raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,016 shares of the medical research company's stock after buying an additioDecember 18, 2024 | marketbeat.comToronto Dominion Bank Sells 2,864 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Toronto Dominion Bank reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,706 shares of the medical research company's stock after selling 2,864 shares during the periodDecember 17, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Sees Significant Decrease in Short InterestBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 488,600 shares, a drop of 6.8% from the November 15th total of 524,400 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average daily volume of 284,500 shares, the short-interest ratio is presently 1.7 days.December 16, 2024 | marketbeat.comBarclays PLC Has $14.04 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Barclays PLC cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 41,976 shares of the medical research company's stock after selling 5,406 shares during the period. BarcDecember 16, 2024 | marketbeat.comFmr LLC Reduces Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Fmr LLC decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 94.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 4,412 shares of the medical research company's stock after selling 72,991 shares during the period.December 16, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Buys 4,138 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Teachers Retirement System of The State of Kentucky boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,5December 12, 2024 | marketbeat.comNeo Ivy Capital Management Takes $878,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Neo Ivy Capital Management acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,626 shares of the medical reDecember 12, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by State Street CorpState Street Corp lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 26.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 635,916 shares of the medical research company's stock after selling 223,975December 12, 2024 | marketbeat.comZacks Investment Management Purchases Shares of 1,620 Bio-Rad Laboratories, Inc. (NYSE:BIO)Zacks Investment Management acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,620 shares of the medical research company's stock, valDecember 11, 2024 | marketbeat.comY Intercept Hong Kong Ltd Buys Shares of 6,679 Bio-Rad Laboratories, Inc. (NYSE:BIO)Y Intercept Hong Kong Ltd purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 6,679 shares of the medical research company's stock,December 10, 2024 | marketbeat.comRoyal Bank of Canada Raises Bio-Rad Laboratories (NYSE:BIO) Price Target to $481.00Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an "outperform" rating in a research report on Monday.December 9, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of "Moderate Buy" by AnalystsBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigneDecember 9, 2024 | marketbeat.comWorldquant Millennium Advisors LLC Boosts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)Worldquant Millennium Advisors LLC boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 43.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,752 shares of the medical research company's stock aftDecember 8, 2024 | marketbeat.comVerition Fund Management LLC Acquires 2,287 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Verition Fund Management LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 193.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,470 shares of the medical research company's stock after acquiring aDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Lowers Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)BNP Paribas Financial Markets cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 58.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,444 shares of the medicalDecember 6, 2024 | marketbeat.comBank of Montreal Can Has $3.13 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Bank of Montreal Can reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 71.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,432 shares of the medical research company's stocDecember 5, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Raised by MetLife Investment Management LLCMetLife Investment Management LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 82.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 9,900 shares of the medical research company's stock after purchasing an additional 4,478 shares duDecember 4, 2024 | marketbeat.comPEAK6 Investments LLC Acquires Shares of 2,857 Bio-Rad Laboratories, Inc. (NYSE:BIO)PEAK6 Investments LLC bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,857 shares of the medical researchDecember 3, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Stake Lifted by Paloma Partners Management CoPaloma Partners Management Co lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 350.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,500 shares of the medical research company'December 2, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Bellevue Group AGBellevue Group AG decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 70.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,151 shares of the medical research company's stock after selling 109,107 shares during theDecember 1, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 4,260 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 1.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 441,098 shares of the medical research company'December 1, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Cerity Partners LLCCerity Partners LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 29.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,793 shares of the medical research company's stock after buying an additional 1,767 shaDecember 1, 2024 | marketbeat.comCitigroup Inc. Trims Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Citigroup Inc. trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 22,501 shares of the medical research company's stock after selling 4,014 shares during the period. CitigroDecember 1, 2024 | marketbeat.comThrivent Financial for Lutherans Buys 3,675 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Thrivent Financial for Lutherans raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 446.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,498 shares of the medical research companDecember 1, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Raises Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)The Manufacturers Life Insurance Company grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 38.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,782November 30, 2024 | marketbeat.com Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BIO Media Mentions By Week BIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIO News Sentiment▼0.800.69▲Average Medical News Sentiment BIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIO Articles This Week▼76▲BIO Articles Average Week Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mettler-Toledo International News Waters News Illumina News Bio-Techne News Bruker News Charles River Laboratories International News Pacific Biosciences of California News Harvard Bioscience News Thermo Fisher Scientific News Agilent Technologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:BIO) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Rad Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIO Stock Alerts